Mizuho analyst Anthony Petrone raised the firm’s price target on ResMed (RMD) to $270 from $250 and keeps an Outperform rating on the shares. The firm adjusted price targets in medical devices and diagnostics ahead of the Q2 reports.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RMD:
- ResMed upgraded to Outperform from Sector Perform at RBC Capital
- Morgan Stanley sees ‘modest’ earnings impact to ResMed from Apnimed
- Apnimed data brings competitive threat to ResMed, says RBC Capital
- Resmed’s Growth Potential Highlighted by Promising Trial Results and Future Opportunities
- Buy Rating for Resmed: Positive Phase 3 Trial Results and Market Conditions Boost AD109’s Appeal